Press Release: Tarveda : Tarveda Therapeutics Presents Promising Phase 2 Data of PEN-221 in Gastrointestinal Mid-gut Neuroendocrine Tumors
WATERTOWN, Mass.--(BUSINESS WIRE)--Tarveda announces data from the GI mid-gut NETs cohort of its Phase 2 clinical trial of PEN-221, presented at the 2021 ASCO Annual Meeting.
Read full article »
Tarveda is a biopharmaceutical company that discovers and develops miniaturized drug conjugates for the treatment of solid tumor malignancies.
Read more